Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(50%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph early_phase_1
1
17%
Ph phase_2
3
50%
Ph phase_3
2
33%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Terminated(2)

Detailed Status

Recruiting2
Terminated1
Withdrawn1
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 32 (33.3%)

Trials by Status

terminated117%
withdrawn117%
completed117%
recruiting233%
active_not_recruiting117%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_2

Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

NCT02081326
recruitingphase_2

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

NCT05180591
recruitingphase_2

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

NCT05866536
completedearly_phase_1

Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US

NCT03175380
withdrawnphase_3

SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I

NCT02254915
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02081326Phase 2

Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

Active Not Recruiting
NCT05180591Phase 2

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

Recruiting
NCT05866536Phase 2

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Recruiting
NCT03175380Early Phase 1

Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US

Completed
NCT02254915Phase 3

SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I

Withdrawn
NCT00384891Phase 3

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6